Saturday 17 October 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.26
0.03
−2.33%
Follow NBP
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 2 | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
6.19 | 6.19 | 6.19 | 16.47 | 15.05 | 1.37 | 9.73 | — | — |
Altman Z-Score |
— | — | — | 16.02 | 11.81 | — | (3.80) | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | (3.05) | 12.42 | 4.45 | — | (5.63) | — | — |
P/Operating CF |
(0.35) | (0.35) | (0.35) | 58.65 | (24.30) | (2.18) | (1.03) | — | — |
Beneish M-Score |
— | — | — | 44.96 | (7.37) | — | — | — | — |
P/B ratio |
0.23 | 0.23 | 0.23 | 4.52 | 5.19 | 0.83 | 0.78 | — | — |
Price to Tangible BV |
0.30 | 0.30 | 0.30 | 4.76 | 5.53 | 0.91 | 0.84 | — | — |
EV/Sales |
(16.57) | (16.57) | (16.57) | 13.42 | 12.39 | (0.60) | (5.58) | — | — |
EV/EBITDA |
1.50 | 1.50 | 1.50 | 27.05 | 26.04 | 0.00 | 0.00 | — | — |
EV/Operating CF |
0.00 | 0.00 | 0.00 | (19.50) | (12.69) | 0.33 | 0.25 | — | — |
EV/FCF |
0.00 | 0.00 | 0.00 | (19.50) | (12.69) | 0.33 | 0.25 | — | — |
Quick Ratio |
3.50 | 5.66 | 3.88 | 8.54 | 6.91 | 4.68 | 5.36 | 20.51 | 7.84 |
Current Ratio |
3.54 | 5.88 | 4.12 | 9.28 | 7.66 | 4.78 | 5.67 | 20.90 | 8.09 |
Net Debt/EBITDA |
(0.91) | (2.60) | 0.76 | (26.76) | 2.08 | 1.85 | 4.39 | 3.44 | 2.26 |
Debt/Assets |
0.00% | 0.00% | 6.80% | 0.13% | 0.55% | 0.47% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(3.08) | (3.21) | 0.09 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.03 | 0.39 | 0.01 | (0.04) | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.85 | 0.70 | 0.58 | 0.92 | 0.42 | 0.44 | 0.35 | 2.37 | 0.45 |
Capex/Depreciation |
0.00 | 0.00 | (0.78) | (0.35) | (0.88) | (0.72) | (0.15) | 0.01 | 0.05 |
Interest Coverage |
(86.43) | (190.84) | (489.37) | 162.19 | (88.35) | (285,546.00) | (706.05) | — | — |
| 47.67% | 65.76% | (826.99%) | 13.71% | (46.37%) | (63.92%) | (62.52%) | (10.02%) | (21.42%) | |
| (17.53%) | 0.00% | (170.93%) | 11.83% | (39.56%) | (49.47%) | (43.30%) | (7.64%) | (19.56%) | |
ROIC |
0.00% | 0.00% | (415.21%) | 11.51% | (413.03%) | 0.00% | 0.00% | (115.77%) | (293.14%) |
Return on Tangible Assets |
(55.39%) | (24.32%) | (139.96%) | 9.83% | (55.47%) | (85.60%) | (75.94%) | (13.20%) | (24.25%) |
Average Days of Receivables |
134.44 | 420.54 | 679.40 | 30.88 | 137.17 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
2,311.16% | 792.15% | 2,801.53% | 63.83% | 1,377.98% | (408.41%) | 3,393.67% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
205.97% | 110.91% | 2,181.97% | 26.09% | 1,022.38% | (368.18%) | 4,455.70% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.18 | 0.04 | 0.05 | 0.07 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1,223.04% | 31.99% | 691.41% | (161.19%) | 1,620.09% | 0.00% | 0.00% |
Graham Net Nets |
3.16 | 3.16 | 3.16 | 0.18 | 0.16 | 1.03 | 1.08 | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
(140.48%) | (140.48%) | (140.48%) | (35.44%) | (5.32%) | (79.95%) | (199.40%) | — | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | (4.18%) | (6.48%) | (133.97%) | (227.29%) | — | — |
Revenue per Share |
0.03 | 0.14 | 1.34 | 4.05 | 0.18 | (0.39) | 0.01 | 0.00 | 0.00 |
Operating CF per Share |
(0.64) | (0.73) | (38.85) | 1.14 | (2.01) | (1.94) | (0.87) | (0.65) | (0.22) |
Capex per Share |
0.00 | 0.00 | (0.55) | (0.02) | (0.06) | (0.08) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.64) | (0.73) | (39.40) | 1.12 | (2.07) | (2.02) | (0.88) | (0.65) | (0.21) |
Cash per Share |
1.79 | 4.75 | 54.85 | 12.59 | 8.84 | 6.23 | 3.75 | 2.14 | 2.20 |
Shareholders Equity per Share |
(0.79) | (2.39) | 59.43 | 14.78 | 9.42 | 5.11 | 2.91 | 2.48 | 2.41 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.79) | (2.39) | 59.43 | 14.78 | 9.42 | 5.11 | 2.91 | 2.48 | 2.41 |
Free Cash Flow |
(37.31) | (42.42) | (126.44) | 65.22 | (157.40) | (166.54) | (72.86) | (52.65) | (20.56) |
Working Capital |
76.24 | 246.25 | 148.09 | 730.66 | 652.44 | 415.87 | 271.77 | 168.24 | 190.63 |
Capital Expenditures |
(3.01) | (2.18) | (1.76) | (1.23) | (4.70) | (6.64) | (0.16) | 0.01 | 0.04 |
Net Current Asset Value |
(50.34) | (188.14) | 136.65 | 710.66 | 586.90 | 357.06 | 203.57 | 165.17 | 187.94 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.41 | 0.01 | 0.34 | (0.21) | 0.25 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.07 | 0.25 | 0.52 | 0.92 | 0.75 | 1.05 | 0.60 | 4.87 | 6.11 |
Cash ROIC |
(18.65%) | (7.27%) | (32.95%) | 4.08% | (11.31%) | (17.74%) | (13.14%) | (14.06%) | (4.65%) |
Accounts Receivable Turnover |
0.34 | 1.63 | 0.50 | 16.88 | 1.10 | (6.45) | 0.00 | — | — |
Accounts Payable Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Days of Inventory on Hand |
— | — | — | — | 214.11 | 0.00 | — | — | — |
Average Receivables |
5.00 | 5.00 | 8.69 | 14.01 | 12.60 | 4.98 | — | — | — |
Average Assets |
251.76 | 0.00 | 124.79 | 610.14 | 924.82 | 734.79 | 479.77 | 290.80 | 236.60 |
Average Common Equity |
(92.57) | (92.57) | 25.79 | 526.55 | 788.95 | 568.70 | 332.24 | 221.87 | 216.05 |
Columns are period end dates · fundamentals updated 1 Oct 2026